Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis

Clinical and Vaccine Immunology

Volumn 13, Issue 2, 2006, Pages 258-265

  Njoku, Dolores B ^a   Mellerson, Jenelle L ^a   Talor, Monica V ^a   Kerr, Douglas R ^b   Faraday, Nauder R ^a   Outschoorn, Ingrid ^c   Rose, Noel R ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; CYTOCHROME P450 2E1; IMMUNOGLOBULIN G4; INHALATION ANESTHETIC AGENT;

ADULT; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; TOXIC HEPATITIS; UNITED STATES;

ADULT; ANESTHESIOLOGY; ANESTHETICS, INHALATION; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; CASE-CONTROL STUDIES; COMPLEMENT SYSTEM PROTEINS; CYTOCHROME P-450 CYP2E1; FEMALE; HEPATITIS, AUTOIMMUNE; HEPATITIS, TOXIC; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; OCCUPATIONAL EXPOSURE;

EID: 33644911180     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.2.258-265.2006     Document Type: Article

References (50)

1. Adkinson, N. F., Jr., D. Essayan, R. Gruchalla, H. Haggerty, T. Kawabata, J. D. Sandler, L. Updyke, N. H. Shear, and D. Wierda. 2002. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J. Allergy Clin. Immunol. 109:S461-S478.
2. Alberti-Flor, J. J., M. E. Hernandez, J. P. Ferrer, S. Howell, and L. Jeffers. 1989. Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim. Am. J. Gastroenterol. 84:1577-1579.
3. Alvarez, F., P. A. Berg, F. B. Bianchi, L. Bianchi, A. K. Burroughs, E. L. Cancado, R. W. Chapman, W. G. Cooksley, A. J. Czaja, V. J. Desmet, P. T. Donaldson, A. L. Eddleston, L. Fainboim, J. Heathcote, J. C. Homberg, J. H. Hoofnagle, S. Kakumu, E. L. Krawitt, I. R. Mackay, R. N. MacSween, W. C. Maddrey, M. P. Manns, I. G. McFarlane, K. H. Meyer zum Buschenfelde, and M. Zeniya. 1999. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31:929-938.
4. Bourdi, M., W. Chen, R. M. Peter, J. L. Martin, J. T. Buters, S. D. Nelson, and L. R. Pohl. 1996. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem. Res. Toxicol. 9:1159-1166.
5. Carroll, M. C. 2000. The role of complement in B cell activation and tolerance. Adv. Immunol. 74:61-88.
6. Castell, J. V. 1998. Allergic hepatitis: a drug-mediated organ-specific immune reaction. Clin. Exp. Allergy 28(Suppl. 4):13-19.
7. Caturegli, P., R. C. Kuppers, S. Mariotti, C. L. Burek, A. Pinchera, P. W. Ladenson, and N. R. Rose. 1994. IgG subclass distribution of thyroglobulin antibodies in patients with thyroid disease. Clin. Exp. Immunol. 98:464-469.
8. Cook, A. D., I. R. Mackay, F. M. Cicuttini, and M. J. Rowley. 1997. IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J. Rheumatol. 24:2090-2096.
9. Couper, J. J., L. C. Harrison, J. J. Aldis, P. G. Colman, M. C. Honeyman, and A. Ferrante. 1998. IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. Hum. Immunol. 59:493-499.
10. Eliasson, E., and J. G. Kenna. 1996. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol. Pharmacol. 50:573-582.
11. Hawlisch, H., M. Wills-Karp, C. L. Karp, and J. Kohl. 2004. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol. Immunol. 41:123-131.
12. Hoet, P., M. L. Graf, M. Bourdi, L. R. Pohl, P. H. Duray, W. Chen, R. M. Peter, S. D. Nelson, N. Verlinden, and D. Lison. 1997. Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 350:556-559.
13. Horneff, G., H. G. Lenard, and V. Wahn. 1992. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics 23:272-275.
14. Ilyas, A. A., Z. W. Chen, S. D. Cook, F. A. Mithen, and B. S. Singhal. 2001. Immunoglobulin G subclass distribution of autoantibodies to gangliosides in patients with Guillain-Barre syndrome. Res. Commun. Mol. Pathol. Pharmacol. 109:115-123.
15. Itoh, S., A. Ichinoe, Y. Tsukada, and Y. Itoh. 1981. Hydralazine-induced hepatitis. Hepatogastroenterology 28:13-16.
16. Kay, R. A., K. J. Wood, R. M. Bernstein, P. J. Holt, and R. S. Pumphrey. 1988. An IgG subclass imbalance in connective tissue disease. Ann. Rheum. Dis. 47:536-541.
17. Kuroki, A., T. Shibata, H. Honda, D. Totsuka, K. Kobayashi, and T. Sugisaki. 2002. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern. Med. 41:936-942.
18. Laroche, D., I. Aimone-Gastin, F. Dubois, H. Huet, P. Gerard, M. C. Vergnaud, C. Mouton-Faivre, J. L. Gueant, M. C. Laxenaire, and H. Bricard. 1998. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology 209:183-190.
19. Lee, W. M., and J. R. Senior. 2005. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol. Pathol. 33:155-164.
20. Locker, J. D., M. E. Medof, R. M. Bennett, and S. Sukhupunyaraksa. 1977. Characterization of DNA used to assay sera for anti-DNA antibodies; determination of the specificities of anti-DNA antibodies in SLE and non-SLE rheumatic disease states. J. Immunol. 118:694-701.
21. Mackay, I. R., and B. H. Toh. 2002. Autoimmune hepatitis: the way we were, the way we are today and the way we hope to be. Autoimmunity 35:293-305.
22. Manns, M. P., E. F. Johnson, K. J. Griffin, E. M. Tan, and K. F. Sullivan. 1989. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J. Clin. Investig. 83:1066-1072.
23. Manolova, I., M. Dancheva, and K. Halacheva. 2002. Predominance of IgG1 and IgG3 subclasses of autoantibodies to neutrophil cytoplasmic antigens in patients with systemic lupus erythematosus. Rheumatol. Int. 21:227-233.
24. Martin, J. L., G. F. Reed, and L. R. Pohl. 1993. Association of anti-58 kDa endoplasmic reticulum antibodies with halothane hepatitis. Biochem. Pharmacol. 46:1247-1250.
25. Masubuchi, Y., M. Bourdi, T. P. Reilly, M. L. Graf, J. W. George, and L. R. Pohl. 2003. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem. Biophys. Res. Commun. 304:207-212.
26. McFarlane, I. G. 1998. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 42:599-602.
27. Meyer, U. A. 2000. Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671.
28. Neuberger, J., G. Mieli-Vergani, J. M. Tredger, M. Davis, and R. Williams. 1981. Oxidative metabolism of halothane in the production of altered hepatocyte membrane antigens in acute halothane-induced hepatic necrosis. Gut 22:669-672.
29. Njoku, D., M. J. Laster, D. H. Gong, E. I. Eger, G. F. Reed, and J. L. Martin. 1997. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth. Analg. 84:173-178.
30. Njoku, D. B., R. S. Greenberg, M. Bourdi, C. B. Borkowf, E. M. Dake, J. L. Martin, and L. R. Pohl. 2002. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth. Analg. 94:243-249.
31. Njoku, D. B., M. V. Talor, D. Fairweather, S. Frisancho-Kiss, O. A. Odumade, and N. R. Rose. 2005. A novel model of drug hapten-induced hepatitis with increased mast cells in the BALB/c mouse. Exp. Mol. Pathol. 78:87-100.
32. Oliveira, D. B. 1998. Membranous nephropathy: an IgG4-mediated disease. Lancet 351:670-671.
33. Ostapowicz, G., R. J. Fontana, F. V. Schiodt, A. Larson, T. J. Davern, S. H. Han, T. M. McCashland, A. O. Shakil, J. E. Hay, L. Hynan, J. S. Crippin, A. T. Blei, G. Samuel, J. Reisch, and W. M. Lee. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137:947-954.
34. Outschoorn, I., M. J. Rowley, A. D. Cook, and I. R. Mackay. 1993. Subclasses of immunoglobulins and autoantibodies in autoimmune diseases. Clin. Immunol. Immunopathol. 66:59-66.
35. Oxelius, V. A. 1984. Immunoglobulin G (IgG) subclasses and human disease. Am. J. Med. 76:7-18.
36. Phillips, K. A., D. L. Veenstra, E. Oren, J. K. Lee, and W. Sadee. 2001. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279.
37. Pohl, L. R., D. Thomassen, N. R. Pumford, L. E. Butler, H. Satoh, V. J. Ferrans, A. Perrone, B. M. Martin, and J. L. Martin. 1991. Hapten carrier conjugates associated with halothane hepatitis. Adv. Exp. Med. Biol. 283:111-120.
38. Rosenberg, J. L., D. Edlow, and R. Sneider. 1978. Liver disease and vasculitis in a patient taking cromolyn. Arch. Intern. Med. 138:989-991.
39. Schiodt, F. V., E. Atillasoy, A. O. Shakil, E. R. Schiff, C. Caldwell, K. V. Kowdley, R. Stribling, J. S. Crippin, S. Flamm, K. A. Somberg, H. Rosen, T. M. McCashland, J. E. Hay, and W. M. Lee. 1999. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl. Surg. 5:29-34.
40. Silva, L. M., J. Chavez, M. H. Canalli, and C. R. Zanetti. 2003. Determination of IgG subclasses and avidity of antithyroid peroxidase antibodies in patients with subclinical hypothyroidism-a comparison with patients with overt hypothyroidism. Horm. Res. 59:118-124.
41. Strey, C. W., M. Markiewski, D. Mastellos, R. Tudoran, L. A. Spruce, L. E. Greenbaum, and J. D. Lambris. 2003. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198:913-923.
42. Temple, R. J., and M. H. Himmel. 2002. Safety of newly approved drugs: implications for prescribing. JAMA 287:2273-2275.
43. Vance, G. H., C. A. Thornton, T. N. Bryant, J. A. Warner, and J. O. Warner. 2004. Ovalbumin-specific immunoglobulin G and subclass responses through the first 5 years of life in relation to duration of egg sensitization and the development of asthma. Clin. Exp. Allergy 34:1542-1549.
44. van der Zee, J. S., P. van Swieten, and R. C. Aalberse. 1986. Inhibition of complement activation by IgG4 antibodies. Clin. Exp. Immunol. 64:415-422.
45. van der Zee, J. S., P. van Swieten, and R. C. Aalberse. 1986. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J. Immunol. 137:3566-3571.
46. Vidali, M., S. F. Stewart, R. Rolla, A. K. Daly, Y. Chen, E. Mottaran, D. E. Jones, J. B. Leathart, C. P. Day, and E. Albano. 2003. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 37:410-419.
47. Warren, S. J., L. A. Arteaga, E. A. Rivitti, V. Aoki, G. Hans-Filho, B. F. Qaqish, M. S. Lin, G. J. Giudice, and L. A. Diaz. 2003. The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J. Investig. Dermatol. 120:104-108.
48. Wen, L., J. P. Atkinson, and P. C. Giclas. 2004. Clinical and laboratory evaluation of complement deficiency. J. Allergy Clin. Immunol. 113:585-593.
49. White, R. H., and D. L. Robbins. 1987. Clinical significance and interpretation of antinuclear antibodies. West. J. Med. 147:210-213.
50. Williams, B. D., N. White, P. L. Amlot, J. Slaney, and P. A. Toseland. 1977. Circulating immune complexes after repeated halothane anaesthesia. Br. Med. J. 2:159-162.